<DOC>
	<DOCNO>NCT01195298</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter study capecitabine bevacizumab administer first-line treatment previously untreated elderly patient , old 70 year , metastatic locally recurrent breast cancer .</brief_summary>
	<brief_title>Bevacizumab Capecitabine Treatment Elderly Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Signed informed consent obtain prior initiation study specific procedure treatment confirmation patient 's awareness willingness comply Protocol code : ML22373 Protocol SEEROG : version 1.2 . Date : October 15 , 2009 3 study requirement ; Age ≥70 year ; Pathologically confirm document metastatic breast cancer locally recurrent breast cancer amenable curative treatment . Complete radiology tumor measurement workup must complete within 4 week prior first study treatment ; Measurable disease accord RECIST criterion ; HER2 negative disease ; No prior treatment metastatic locally recurrent disease ; Prior radiotherapy allow deliver least 2 week enrolment study relief metastatic bone pain , provide 30 % marrow bear bone irradiate target lesion include radiotherapy field ; Not suitable aggressive chemotherapy regimen opinion investigator ; Performance status ECOG 0 2 . Any prior neoadjuvant adjuvant treatment anthracyclines complete less 6 month prior enrolment . The maximum cumulative dose receive must exceed 360 mg/m2 doxorubicin 720 mg/m2 epirubicin . Prior antiepidermal growth factor therapy allow ; Concurrent hormonal therapy ; however previous hormonal therapy allow adjuvant , locally recurrent , metastatic breast cancer complete within ≥1 month prior enrolment ; History clinical evidence brain metastasis . If clinical suspicion brain metastasis , computerize tomography ( CT ) scan magnetic resonance imaging ( MRI ) brain must conduct within 4 week prior enrolment ; Other malignancy ( include primary brain tumor ) within Protocol code : ML22373 Protocol SEEROG : version 1.2 . Date : October 15 , 2009 4 last 5 year , could affect diagnosis assessment breast cancer , except adequately treat carcinoma situ cervix , squamous carcinoma skin , adequately control limited basal cell skin cancer ; Life expectancy &lt; 12 week ; Any follow abnormal value : Inadequate bone marrow function : hemoglobin ( Hb ) &lt; 8.0 g/dL , absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L , platelet count &lt; 100 x 109/L ; Inadequate liver function : AST/SGOT ALT/SGPT &gt; 2.5 x upper limit normal ( ULN ) &gt; 5 x ULN patient liver metastasis ) , serum alkaline phosphatase &gt; 2.5 ULN &gt; 5 x ULN patient liver metastasis , &gt; 10 x ULN patient bone metastases total bilirubin &gt; 2 x ULN ; Moderate severe renal impairment : creatinine clearance ≤50 mL/min ( calculate accord cockcroft Gault formula ; see Appendix 1 ) , serum creatinine &gt; 1.5 x ULN ; Chronic daily treatment aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75 mg / day ) ; Chronic daily treatment corticosteroid ( dose &gt; 10 mg/day methylprednisolone equivalent ) ( exclude inhale steroid ) ; Requirement concurrent use antiviral agent sorivudine brivudine ; Major surgical procedure , open biopsy significant traumatic injury within 28 day prior enrolment , anticipation need major surgery course study treatment ; Minor surgical procedure , within 24 hour prior enrolment ; Current recent ( within 30 day prior start study treatment ) treatment another investigational drug participation another investigational study . Uncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg ) clinically significant ( i.e . active ) cardiovascular disease , include : Cerebrovascular accident/stroke ( ≤ 6 month prior enrolment )</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>elderly patient</keyword>
	<keyword>chemoimmunotherapy</keyword>
	<keyword>Triple negative metastatic breast cancer</keyword>
</DOC>